Glucagon-like peptide-1 (GLP-1) analogs, currently used to treat T2DM and obesity, have effectively reduced appetite and slowed gastric emptying, thereby facilitating weight and body fat mass reduction [24]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.